On March 8, 2022 Johnson & Johnson reported that it is currently talking with two China biopharmas about forming partnerships, though it did not name either company (Press release, Johnson & Johnson, MAR 8, 2022, View Source [SID1234609974]). J&J has a very good reason for being interested in China . Four years ago, its subsidiary, Janssen Pharma, formed a $1 billion partnership for Nanjing Legend Bio’s CAR-T multiple myeloma therapy. At the time Legend wasn’t particularly well known, but its CAR-T posted very high efficacy rates in a early trial. One week ago, Carvykti (cilta-cel) was approved for a US launch.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!